| Title |
Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
|
|---|---|
| Published in |
HIV/AIDS (Auckland, N.Z.), July 2011
|
| DOI | 10.2147/hiv.s14561 |
| Pubmed ID | |
| Authors |
Roger Bedimo |
| Abstract |
HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known, including peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertrophy). These changes may cause significant patient distress, which could in turn interfere with adherence to antiretroviral therapy. Treatment options - including antiretroviral switch, insulin sensitizers, and surgical approaches - have been associated with limited success and potential complications. The observation that low growth hormone levels are associated with central fat accumulation among HIV patients has led to the development of tesamorelin (a growth hormone releasing hormone analog) for the management of central fat accumulation. Randomized controlled trials have shown that administration of tesamorelin is safe and effective in reducing central fat accumulation among HIV-infected patients. This effect is transient, however, and its association with improved cardiovascular risk remains unclear. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 4% |
| Unknown | 25 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 3 | 12% |
| Researcher | 3 | 12% |
| Student > Master | 3 | 12% |
| Student > Postgraduate | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Other | 3 | 12% |
| Unknown | 10 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 19% |
| Agricultural and Biological Sciences | 4 | 15% |
| Nursing and Health Professions | 3 | 12% |
| Immunology and Microbiology | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 10 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 November 2023.
All research outputs
#3,274,342
of 25,373,627 outputs
Outputs from HIV/AIDS (Auckland, N.Z.)
#23
of 330 outputs
Outputs of similar age
#16,048
of 127,138 outputs
Outputs of similar age from HIV/AIDS (Auckland, N.Z.)
#1
of 3 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 330 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 127,138 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them